ARTICLE | Company News
InSite, Bausch & Lomb deal
January 5, 2004 8:00 AM UTC
ISV sold to BOL its ISV-403 to treat ocular bacterial infections. ISV received a cash payment and reimbursement for product development expenses, and is eligible for royalties. The sale cancels the c...